Sharp Fluidics recently announced the launch of the NeoClose AnchorGuard, designed to enable clinicians to close laparoscopic and robotic port sites without insufflation.
This is the first port site technology that can be used with any brand trocar that meets the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) recommended guidelines for safe closure of laparoscopic and robotic port sites, according to the company.
NeoClose uses bio-absorbable anchors with a pre-attached suture. It is designed to work faster and safer and to provide less port-site pain than the standard practice of closing port sites.
“Sharp Fluidics continues to innovate to make closure safer and faster for clinicians,” said Sharp Fluidics president Douglas Rimer in a news release. “We look forward to bringing this technology to hospitals across the country to help reduce COVID-19 exposure in the operating room.”